Status:
COMPLETED
Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in "Treat-and-extend" at CHU Brugmann
Lead Sponsor:
Laurence Postelmans
Conditions:
Age-related Macular Degeneration
Eligibility:
All Genders
50+ years
Brief Summary
Age-related macular degeneration (AMD) is a leading cause of blindness in people over 50. Neovascular AMD, the most serious and severe form, is characterized by the appearance, spread and growth of su...
Eligibility Criteria
Inclusion
- Patients\> 50 years old diagnosed with neovascular age related macular degeneration,
- Patients who have never received anti-VEGF treatment,
- Patients who started intra-vitreous injections of aflibercept between 01 January 2014 and November 30, 2019,
- Treatment by "treat-and-extend" directly after the loading dose of aflibercept,
- Availability of the medical file reporting treatment with aflibercept.
Exclusion
- Participation in an interventional clinical study during treatment with aflibercept,
- Patients with ocular pathologies who required surgery during the first 24 months of treatment with aflibercept (eg advanced glaucoma or cataracts).
Key Trial Info
Start Date :
April 13 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 22 2021
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT04891835
Start Date
April 13 2021
End Date
September 22 2021
Last Update
March 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Brugmann
Brussels, Belgium, 1020